Design
A randomized, double-blind, sham-controlled within-subjects trial design was employed, in which participants received different tDCS protocols (sham tDCS, 1.5mA tDCS, and 3.0mA tDCS). A two-week interval was incorporated between the experimental sessions to mitigate any carryover effects. The research is in line with the Declaration of Helsinki, and it received the approval of the Ethics Committee of the Ghent University Hospital (UZ Ghent - B6702021000839). The study was conducted at the Ghent University Hospital of Ghent University, from March 2022 to March 2023. The current study is part of a larger project (Razza, De Smet, et al., 2023).